All Oncology News

Ibrutinib given prior to apheresis was associated with improved outcomes with tisagenlecleucel vs post-apheresis administration in relapsed/refractory LBCL.

R. Lor Randall, MD, FACS, highlights a recent meta-analysis comparing 2 approaches to surgical management for patients with femoral metastases.

The novel ADC DB-1311/BNT324 was effective in cervical cancer and PROC, regardless of prior treatment or histology

The B7-H3–targeting ADC demonstrated encouraging responses across multiple gynecologic cancers in a phase 1/2 trial.

Single-agent rezatapopt showed efficacy and safety irrespective of platinum status, prior bevacizumab or PARP inhibitor exposure, or FRα expression.

The B7-H4–targeted ADC produced ORRs of 62% and 67% in patients with PROC and endometrial cancer, respectively, in the phase 1 BEHOLD-1 study.

The top 5 OncLive TV videos of the week cover insights in mantle cell lymphoma, chronic lymphocytic leukemia, salivary gland cancer, cholangiocarcinoma, and prostate cancer.

Cadonilimab combined with chemotherapy demonstrated robust efficacy and a favorable safety profile in advanced or recurrent endometrial cancer.

Patients who received first-line niraparib as maintenance therapy had high resolution rates and low number of discontinuations due to hematologic PSEOIs.

A significant increase in treatment completion was observed among Black women with high-risk endometrial cancer who received 1:1 peer support.

Trastuzumab pamirtecan achieved ~50% ORR in pretreated HER2-expressing endometrial cancer, earning FDA breakthrough designation per phase 1/2 trial data.

With 1 year of additional follow-up, avutometinib plus defactinib showed durable efficacy with no new safety concerns in LGSOC.

Results from NRG-GY019 establish chemotherapy followed by letrozole as the definitive SOC for newly diagnosed stage II-IV low-grade serous ovarian carcinoma

Abemaciclib plus letrozole was safe and active in advanced/recurrent endometrioid endometrial carcinoma.

Relacorilant plus nab-paclitaxel cuts death risk by 35% and extends survival to 16 months in platinum-resistant ovarian cancer, per final ROSELLA trial data.

The FDA issued a CRL to RP1 plus nivolumab in advanced melanoma, accepted a NDA for the TLX101-Px imaging agent in glioma, and more.

Zosia Piotrowska, MD, MHS, discusses potential new TKIs, continued challenges, and ongoing frontline trials in EGFR exon 20 insertion–positive NSCLC

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Researchers used a genome-wide CRISPR knockout screen to pinpoint genes that help human AML cells avoid being engulfed by macrophages.

The FDA issued a CRL to RP1 plus nivolumab for the management of advanced melanoma after progression on an anti–PD-1–containing regimen.

An NDA seeking the approval of TLX101-Px for characterizing treatment-related changes in recurrent or progressive glioma has been accepted by the FDA.

Maurie Markman, MD, unpacks goals-of-care discussions in oncology.

Manish Patel, DO, discusses early evidence suggesting that AR inhibition may enhance the efficacy of immunotherapy in salivary gland cancer.

Zevor-cel produced durable responses in patients with relapsed/refractory multiple myeloma following at least 3 prior lines of therapy.

Lore Gruenbaum, PhD, discusses hot topics in mantle cell lymphoma like recently approved CAR T-cell therapies and where she sees the field moving next.

ASCO has published updates to the clinical practice guidelines for the use of systemic therapy across subsets of patients with thyroid cancer.

A BLA has been accepted in China seeking the approval of second-line trastuzumab pamirtecan for unresectable or metastatic HER2-positive breast cancer.

A large U.S. study showed that adults who have never been married face a significantly higher risk of developing cancer than those who have been married.

Sagar S. Patel, MD, discusses data from trials evaluating agents in the Orca platform and where they fit into hematologic malignancy treatment paradigms.

During an Onclive Peer Exchange, panelists examined the utility of ctDNA in bladder cancer and other GU malignancies.